DM
INZY

Deerfield Management’s Inozyme Pharma INZY Stock Holding History

Deerfield Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,591
Closed -$51.7K – 550
2024
Q2 		$51.7K Buy
+11,591
New +$56.2K ﹤0.01% 426
2022
Q4 		– Sell
-2,090,436
Closed -$5.6M – 112
2022
Q3 		$5.6M Sell
2,090,436
-605,936
-22% -$2.19M 0.11% 94
2022
Q2 		$12.9M Buy
2,696,372
+351,586
+15% +$1.53M 0.27% 71
2022
Q1 		$9.59M Hold
2,344,786
– – 0.21% 75
2021
Q4 		$16M Hold
2,344,786
– – 0.34% 67
2021
Q3 		$27.2M Buy
2,344,786
+165,801
+8% +$2.59M 0.53% 54
2021
Q2 		$37.1M Buy
2,178,985
+214,985
+11% +$3.74M 0.66% 51
2021
Q1 		$38.9M Buy
1,964,000
+813,701
+71% +$18M 0.82% 43
2020
Q4 		$23.7M Hold
1,150,299
– – 0.47% 65
2020
Q3 		$30.2M Buy
+1,150,299
New +$28.6M 0.74% 39

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management's INZY Position: Q3 2024 in Review

Deerfield Management sold out of Inozyme Pharma (INZY) in Q3 2024, closing a stake of 11,591 shares — an estimated $51.7K sold.

Deerfield Management first reported a position in INZY in Q3 2020 and held it in 10 quarters. The position peaked at $38.9M in Q1 2021. 89 funds tracked by Wall St. Rank hold INZY as of Q3 2024.

  • Deerfield Management reported no remaining Inozyme Pharma position as of Q3 2024 after selling out during the quarter.
  • Deerfield Management sold 11,591 Inozyme Pharma shares in Q3 2024, an estimated $51.7K.
  • Deerfield Management first reported a position in Inozyme Pharma in Q3 2020 and held it in 10 quarters.
  • Deerfield Management's Inozyme Pharma position peaked at $38.9M in Q1 2021.
  • 89 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2024.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.